Browsing by Author "Mota-Pereira, J."
Now showing 1 - 2 of 2
Results Per Page
Sort Options
- Influence of Il-18 genetic polymorphisms in antidepressant treatment phenotypesPublication . Santos, Marlene; Carvalho, S.; Lima, L.; Mota-Pereira, J.; Pimentel, P.; Maia, D.; Correia, D.; Gomes, S.; Cruz, Agostinho; Medeiros, R.Recent studies suggested that immune activation and cytokines might be involved in depression. The proinflammatory cytokine interleukin-18 (IL-18) is less reported in depression but is still relevant since it is expressed in the brain and serum levels of IL-18 have been found to be increased in patients with moderate to severe depression. Therefore, it seems reasonable that IL-18 promoter SNPs may have an effect in antidepressant response phenotypes.
- Role of genetic polymorphisms on neuroplasticity pathways in a cohort of Portuguese patients with Major Depressive DisorderPublication . Santos, M.; Carvalho, S.; Lima, L.; Mota-Pereira, J.; Pimentel, P.; Correia, D.; Maia, D.; Gomes, S.; Cruz, A.; Medeiros, R.Growing evidence suggests the implication of brain plasticity in antidepressant drug (AD) efficacy. Several authors have been pointing out the role of the BDNF-TrkB signaling pathway, including the downstream kinases Akt and ERK, and the mTOR pathway in neuroplasticity [1-3]. Furthermore, the prediction of AD response phenotypes of depressed patients treated with AD drugs remains a challenge for clinicians. Although previous studies have suggested that genetic variants may play a key role in the mechanism of Treatment Resistance Depression and Relapse, attempts to identify risk polymorphisms within genes with putative interest in AD response, had a limited success.